New oral medication shows promise for more quickly treating MRSA skin infections, researchers find

Share this article:

A new oral antibiotic may effectively treat MRSA-related skin infections more quickly than the only oral drug currently approved, according to research published Wednesday in the Journal of the American Medical Association.

Researchers led by Philippe Prokocimer, M.D., the chief medical officer at Trius Therapeutics Inc., compared the effectiveness of tedizolid phosphate with linezolid. Linezolid is the only oral medication currently approved to treat certain skin infections caused by methicillin-resistant Staphylococcus Aureus (MRSA).

The acute bacterial skin and skin structure infections (SSSIs) caused by MRSA can be fatal, and there have been outbreaks of linezolid-resistant strains of MRSA, the researchers noted.

In a 667-person trial carried out in North America, Latin America and Europe, participants received either a daily dose of tedizolid phosphate for six days or a dose of linezolid every 12 hours for 10 days.

Based on clinical outcomes, the researchers determined the newer drug is “clinically noninferior” to linezolid.

Nursing homes experience a high rate of community-associated MRSA, according to a study in the March issue of Infection Control and Hospital Epidemiology.

Share this article:
close

Next Article in News

More in News

Profile: AHCA's money player

Profile: AHCA's money player

If there's a prevailing theme around the hours American Health Care Association senior fellow Elise Smith keeps, it's that they are constant.

Residents cheer tractor parade

Residents cheer tractor parade

Many residents of the Oskaloosa Care Center in southern Iowa used to be farmers. They're reminded of their past by the cornfield next to the nursing home — and, once ...

No need for injury

No need for injury

Due to dynamic factors in moving residents, facilities must invest wisely in lifts, slings and batteries to make sure workers stay safe while performing transfers